Bio-Rad Laboratories, Inc., a global leader in life science research and clinical diagnostic products, today announced the launch of its first ultrasensitive multiplexed digital PCR assay, the ddPLEX ...
In recent years, liquid biopsy approaches have emerged as powerful tools in oncology, enabling non‑invasive, real‑time insights into tumor dynamics. Among these technologies, droplet digital PCR ...
According to the World Health Organization, cancer diagnoses remain a leading cause of death. However, scientific and medical communities have improved clinical outcomes for many people, transforming ...
Bio-Rad Laboratories Inc. (NYSE: BIO and BIOb) today announced the launch of an assay website that allows droplet digital PCR (ddPCR™) users to locate existing assays or design new ones for mutation ...
A CRISPR system detects rare cancer mutations in blood with single-nucleotide precision, outperforming ddPCR through engineered RNA guides and isothermal amplification. (Nanowerk Spotlight) Hidden ...
Biodesix, Inc., a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and ...
Oct. 7, 2005 — The U.S. Food and Drug Administration (FDA) has approved an assay for the detection of epidermal growth factor receptor mutations in patients with non-small cell lung cancer; a D-dimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback